Companies Select Medical Holdings Corp
Select Medical (SEM): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Select Medical Holdings Corp’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $4,842,138FY2024
- $3,042,527FY2025
CEO total pay was $3,042,527 in fiscal 2025, down from $4,842,138 in fiscal 2024.
FY2025: salary $618,000 · stock awards $1,425,000 · option awards $0
Executives and directors
John Saich · PresidentRobert Ortenzio · ExecutiveMartin Jackson · EVPMichael Malatesta · CFOThomas Mullin · CEODavid Chernow · Vice ChairmanDaniel J. Thomas · Independent DirectorJames S. Ely III · Independent DirectorKatherine R. Davisson · Independent DirectorMarilyn B. Tavenner · Independent DirectorParvinderjit S. Khanuja · Independent DirectorRussell L. Carson · Lead Independent DirectorThomas A. Scully · Independent DirectorWilliam H. Frist · Independent Director
Frequently asked questions
Who was the highest-paid executive at Select Medical Holdings Corp in fiscal 2025?
As disclosed, Robert Ortenzio (Executive Chairman and Co-Founder) was the highest-paid executive at Select Medical Holdings Corp in fiscal 2025, with total compensation of $6,615,969.
What is Select Medical Holdings Corp's CEO-to-median employee pay ratio?
As disclosed, Select Medical Holdings Corp's CEO-to-median employee pay ratio was 41:1.
How did shareholders vote on Select Medical Holdings Corp's executive compensation?
As disclosed, 97.07% of shareholders supported Select Medical Holdings Corp's executive compensation in the latest say-on-pay vote.
How much does Select Medical Holdings Corp spend in total on board compensation for fiscal 2025?
As disclosed, Select Medical Holdings Corp reported total board compensation of $2,590,900 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Ortenzio | $995,000 | — | $3,562,500 | $0 | $1,890,500 | $0 | $167,969 | $6,615,969 |
| Executive Chairman and Co-Founder | ||||||||
| David Chernow | 995,000 | — | 3,562,500 | 0 | 1,890,500 | 0 | 94,405 | 6,542,405 |
| Vice Chairman | ||||||||
| Martin Jackson | 700,000 | — | 2,137,500 | 0 | 1,064,000 | 0 | 109,691 | 4,011,191 |
| Senior Executive Vice President of Strategic Finance and Operations | ||||||||
| Thomas Mullin | 618,000 | — | 1,425,000 | 0 | 939,360 | 0 | 60,167 | 3,042,527 |
| Chief Executive Officer | ||||||||
| John Saich | 618,000 | — | 1,425,000 | 0 | 939,360 | 0 | 53,167 | 3,035,527 |
| President | ||||||||
| Michael Malatesta | 585,000 | — | 1,068,750 | 0 | 889,200 | 0 | 38,397 | 2,581,347 |
| Executive Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Robert Ortenzio | $6,615,969 | $10,343,119 | $10,771,792 | ↓ −3,727,150 |
| David Chernow | 6,542,405 | 10,311,733 | 10,706,265 | ↓ −3,769,328 |
| Martin Jackson | 4,011,191 | 6,199,755 | 6,468,839 | ↓ −2,188,564 |
| Thomas Mullin | 3,042,527 | 4,842,138 | — | ↓ −1,799,611 |
| John Saich | 3,035,527 | — | — | — |
| Michael Malatesta | 2,581,347 | 3,952,697 | 1,526,244 | ↓ −1,371,350 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation philosophy for NEOs is designed with the primary goals of rewarding the contributions of NEOs to the Company's financial performance and providing overall compensation sufficient to attract and retain highly skilled NEOs who are properly motivated to contribute to the Company's financial performance.
| CEO STI target (% of salary) | 80% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | not disclosed |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| John Saich | RSU | 2025-07-29 | — | — | 100,000 | — | $1,425,000 |
| Thomas Mullin | RSU | 2025-07-29 | — | — | 100,000 | — | 1,425,000 |
| Michael Malatesta | RSU | 2025-07-29 | — | — | 75,000 | — | 1,068,750 |
| Martin Jackson | RSU | 2025-07-29 | — | — | 150,000 | — | 2,137,500 |
| Robert Ortenzio | RSU | 2025-07-29 | — | — | 250,000 | — | 3,562,500 |
| David Chernow | RSU | 2025-07-29 | — | — | 250,000 | — | 3,562,500 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| John Saich | $1,425,000 | $0 | $0 | 0.0% |
| Thomas Mullin | 1,425,000 | 0 | 0 | 0.0% |
| Michael Malatesta | 1,068,750 | 0 | 0 | 0.0% |
| Martin Jackson | 2,137,500 | 0 | 0 | 0.0% |
| Robert Ortenzio | 3,562,500 | 0 | 0 | 0.0% |
| David Chernow | 3,562,500 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael Malatesta | RSU | 16,667 | — | $247,505 |
| Martin Jackson | RSU | 33,334 | — | 495,009 |
| Michael Malatesta | RSU | 50,000 | — | 742,500 |
| Thomas Mullin | RSU | 50,000 | — | 742,500 |
| John Saich | RSU | 50,000 | — | 742,500 |
| David Chernow | RSU | 55,555 | — | 824,992 |
| Robert Ortenzio | RSU | 55,556 | — | 825,007 |
| Martin Jackson | RSU | 61,333 | — | 910,795 |
| Thomas Mullin | RSU | 66,667 | — | 990,005 |
| John Saich | RSU | 66,667 | — | 990,005 |
| Michael Malatesta | RSU | 75,000 | — | 1,113,750 |
| Thomas Mullin | RSU | 100,000 | — | 1,485,000 |
| John Saich | RSU | 100,000 | — | 1,485,000 |
| David Chernow | RSU | 102,222 | — | 1,517,997 |
| Robert Ortenzio | RSU | 102,222 | — | 1,517,997 |
| Martin Jackson | RSU | 150,000 | — | 2,227,500 |
| David Chernow | RSU | 250,000 | — | 3,712,500 |
| Robert Ortenzio | RSU | 250,000 | — | 3,712,500 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Daniel J. ThomasIndependent · Audit and Compliance · Compensation (Chair) | $164,000 | $199,999 | $0 | $0 | $0 | $363,999 |
| Katherine R. DavissonIndependent · Audit and Compliance · Compensation · Quality of Care and Patient Safety | 162,000 | 199,999 | 0 | 0 | 0 | 361,999 |
| James S. Ely IIIIndependent · Audit and Compliance (Chair) · Nominating/Governance | 158,500 | 199,999 | 0 | 0 | 0 | 358,499 |
| William H. FristIndependent · Audit and Compliance · Quality of Care and Patient Safety (Chair) | 116,508 | 199,999 | 0 | 0 | 0 | 316,507 |
| Parvinderjit S. KhanujaIndependent · Audit and Compliance · Quality of Care and Patient Safety | 113,000 | 199,999 | 0 | 0 | 0 | 312,999 |
| Marilyn B. TavennerIndependent · Nominating/Governance (Chair) · Quality of Care and Patient Safety | 100,600 | 199,999 | 0 | 0 | 0 | 300,599 |
| Russell L. CarsonIndependent · Lead Independent Director · Nominating/Governance | 90,400 | 199,999 | 0 | 0 | 0 | 290,399 |
| Thomas A. ScullyIndependent · Compensation | 85,900 | 199,999 | 0 | 0 | 0 | 285,899 |
| Robert A. OrtenzioEmployee director · Board Chair | 0 | 0 | 0 | 0 | 0 | 0 |
| David ChernowEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $72,000 |
|---|---|
| Annual equity retainer | $199,999 |
| Per board meeting fee | $3,000 |
| Committee chair fees (audit / comp / nom-gov) | 4,000 |
| Stock ownership guideline | Details on the Company’s stock ownership requirements, which apply to the Company’s non-employee directors, are included in the Section titled “Director Compensation” under “Executive Compensation Discussion and Analysis” above. |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $990,908 |
| Equity awards (grant-date value) | $1,599,992 |
| All other compensation | $0 |
| Total cost of the board | $2,590,900 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Select Medical as a peer
Companies that benchmark against SEM
19 companies name SEM as a compensation peer
The list of companies that name SEM as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Select Medical Holdings Corp | 2025 | Thomas Mullin | $618,000 | $1,425,000 | $0 | $939,360 | $3,042,527 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-04-23 | 110,664,208 | 3,339,567 | 33,630 | 97.07% | Passed |
| 2025 | 2025-04-24 | 108,011,565 | 11,314,550 | 594,313 | 90.07% | Passed |
| 2024 | 2024-04-26 | 106,777,980 | 14,125,946 | 42,832 | 88.29% | Passed |
| 2023 | 2023-04-27 | 107,662,511 | 14,902,617 | 225,842 | 87.68% | Passed |
| 2022 | 2022-04-28 | 108,422,682 | 16,580,508 | 44,974 | 86.7% | Passed |
| 2021 | 2021-04-29 | 120,908,105 | 4,981,174 | 376,509 | 95.76% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-04-23 | 97.07%a |
| 2025 | 2025-04-24 | 90.07%b |
| 2024 | 2024-04-26 | 88.29%c |
a. Approved under the standard stated in the filing — “With respect to Proposal 1, because directors are elected by a majority vote, meaning the votes validly cast for such nominee's election exceeds the votes validly cast against such nominee's election in such election, in uncontested elections, abstentions and broker non-votes will not be counted as a vote cast either for or against such director's election.”.
b. Approved under the standard stated in the filing — “Because Proposals 3, 4, 5 and 6 require for approval the affirmative vote of a majority of the shares present online or represented by proxy at the Annual Meeting and entitled to vote, abstentions and broker non-votes will have the same effect as negative votes against these proposals.”.
c. Approved under the standard stated in the filing — “Because Proposals 2, 3, 4 and 6 require for approval the affirmative vote of a majority of the shares present online or represented by proxy at the Annual Meeting and entitled to vote any abstentions will have the effect of votes against and any broker non-votes will not have any effect on these proposals.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 41 : 1 |
|---|---|
| CEO total compensation | $3,042,527 |
| Median employee compensation | $73,571 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| William H. Frist | Director | 2026-04-28 | A | 1,094 | $16 | $17,996 | Common | Form 4 ↗ |
| David Chernow | Director | 2026-04-30 | D | 22,586 | 16 | 370,636 | Common | Form 4 ↗ |
| Robert G. Breighner JR | Senior Vice President | 2026-05-04 | D | 1,330 | 16 | 21,865 | Common | Form 4 ↗ |
| Martin Jackson | Executive Vice President | 2026-06-30 | D | 2,634 | 0 | 0 | Common, indirect | Form 4 ↗ |
| John F. Duggan | Executive Vice President | 2026-06-30 | D | 194,710 | 0 | 0 | Common | Form 4 ↗ |
| Robert G. Breighner JR | Senior Vice President | 2026-06-30 | D | 18,362 | 17 | 302,973 | Common | Form 4 ↗ |
| Parvinderjit S. Khanuja | Director | 2026-06-30 | D | 79,124 | 17 | 1,305,546 | Common | Form 4 ↗ |
| Katherine R. Davisson | Director | 2026-06-30 | D | 60,035 | 17 | 990,578 | Common | Form 4 ↗ |
| Thomas A. Scully | Director | 2026-06-30 | D | 103,424 | 17 | 1,706,496 | Common | Form 4 ↗ |
| Russell L. Carson | Director | 2026-06-30 | D | 610,035 | 0 | 0 | Common | Form 4 ↗ |
| Robert A. Ortenzio | Director | 2026-06-30 | D | 280,415 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Robert A. Ortenzio | Director | 2026-06-30 | D | 280,415 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Robert A. Ortenzio | Director | 2026-06-30 | D | 1,000,000 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Robert A. Ortenzio | Director | 2026-06-30 | D | 7,081,788 | 0 | 0 | Common | Form 4 ↗ |
| Brian R. Rusignuolo | Executive Vice President | 2026-06-30 | D | 361,370 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Weigl | Senior Vice President | 2026-06-30 | D | 1,872 | 17 | 30,888 | Common | Form 4 ↗ |
| David Chernow | Director | 2026-06-30 | D | 113,421 | 17 | 1,871,447 | Common | Form 4 ↗ |
| David Chernow | Director | 2026-06-30 | D | 656,823 | 17 | 10,837,580 | Common | Form 4 ↗ |
| David Chernow | Director | 2026-06-30 | D | 100,000 | 0 | 0 | Common | Form 4 ↗ |
| Robert A. Ortenzio | Director | 2026-06-30 | D | 280,415 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Robert G. Breighner JR | Senior Vice President | 2026-06-30 | D | 16,334 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Weigl | Senior Vice President | 2026-06-30 | D | 12,382 | 17 | 204,303 | Common | Form 4 ↗ |
| Christopher Weigl | Senior Vice President | 2026-06-30 | D | 40,000 | 0 | 0 | Common | Form 4 ↗ |
| Martin Jackson | Executive Vice President | 2026-06-30 | D | 1,383,421 | 0 | 0 | Common | Form 4 ↗ |
| Thomas Mullin | Chief Executive Officer | 2026-06-30 | D | 391,709 | 0 | 0 | Common | Form 4 ↗ |
| Robert A. Ortenzio | Director | 2026-06-30 | D | 279,000 | 17 | 4,603,500 | Common, indirect | Form 4 ↗ |
| Michael Malatesta | Chief Financial Officer | 2026-06-30 | D | 238,057 | 0 | 0 | Common | Form 4 ↗ |
| James S. Ely III | Director | 2026-06-30 | D | 161,674 | 17 | 2,667,621 | Common | Form 4 ↗ |
| Daniel J. Thomas | Director | 2026-06-30 | D | 80,035 | 17 | 1,320,578 | Common | Form 4 ↗ |
| Marilyn B. Tavenner | Director | 2026-06-30 | D | 36,035 | 17 | 594,578 | Common | Form 4 ↗ |
| John Saich | President | 2026-06-30 | D | 736,412 | 0 | 0 | Common | Form 4 ↗ |
| Martin Jackson | Executive Vice President | 2026-06-30 | D | 2,634 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Martin Jackson | Executive Vice President | 2026-06-30 | D | 2,634 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Martin Jackson | Executive Vice President | 2026-06-30 | D | 2,634 | 0 | 0 | Common, indirect | Form 4 ↗ |
| John Tyler Hollenbach | Executive Vice President | 2026-06-30 | D | 135,084 | 0 | 0 | Common | Form 4 ↗ |
| William H. Frist | Director | 2026-06-30 | D | 306,266 | 17 | 5,053,389 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (66 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Robert Ortenzio. DEF 14A, filed 2026-03-04. Section “Summary Compensation Table”. As printed: 6,615,969. View filing ↗
- Section 01, David Chernow. DEF 14A, filed 2026-03-04. Section “Summary Compensation Table”. As printed: 6,542,405. View filing ↗
- Section 01, Martin Jackson. DEF 14A, filed 2026-03-04. Section “Summary Compensation Table”. As printed: 4,011,191. View filing ↗
- Section 01, Thomas Mullin. DEF 14A, filed 2026-03-04. Section “Summary Compensation Table” · page 22. As printed: 3,042,527. View filing ↗
- Section 01, John Saich. DEF 14A, filed 2026-03-04. Section “Summary Compensation Table”. As printed: 3,035,527. View filing ↗
- Section 01, Michael Malatesta. DEF 14A, filed 2026-03-04. Section “Summary Compensation Table”. As printed: 2,581,347. View filing ↗
- Section 03, John Saich RSU. DEF 14A, filed 2026-03-04. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Thomas Mullin RSU. DEF 14A, filed 2026-03-04. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Malatesta RSU. DEF 14A, filed 2026-03-04. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Martin Jackson RSU. DEF 14A, filed 2026-03-04. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Ortenzio RSU. DEF 14A, filed 2026-03-04. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Chernow RSU. DEF 14A, filed 2026-03-04. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-04. Section “CEO Pay Ratio”. As printed: 41 : 1. View filing ↗
- Section 08, Daniel J. Thomas. DEF 14A, filed 2026-03-04. Section “Director Compensation”. As printed: 363,999. View filing ↗
- Section 08, Katherine R. Davisson. DEF 14A, filed 2026-03-04. Section “Director Compensation”. As printed: 361,999. View filing ↗
- Section 08, James S. Ely III. DEF 14A, filed 2026-03-04. Section “Director Compensation”. As printed: 358,499. View filing ↗
- Section 08, William H. Frist. DEF 14A, filed 2026-03-04. Section “Director Compensation”. As printed: 316,507. View filing ↗
- Section 08, Parvinderjit S. Khanuja. DEF 14A, filed 2026-03-04. Section “Director Compensation”. As printed: 312,999. View filing ↗
- Section 08, Marilyn B. Tavenner. DEF 14A, filed 2026-03-04. Section “Director Compensation”. As printed: 300,599. View filing ↗
- Section 08, Russell L. Carson. DEF 14A, filed 2026-03-04. Section “Director Compensation”. As printed: 290,399. View filing ↗
- Section 08, Thomas A. Scully. DEF 14A, filed 2026-03-04. Section “Director Compensation”. As printed: 285,899. View filing ↗
- Section 08, Robert A. Ortenzio. DEF 14A, filed 2026-03-04. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, David Chernow. DEF 14A, filed 2026-03-04. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, William H. Frist 2026-04-28. Form 4, filed 2026-04-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Chernow 2026-04-30. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert G. Breighner JR 2026-05-04. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martin Jackson 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John F. Duggan 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert G. Breighner JR 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Parvinderjit S. Khanuja 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine R. Davisson 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas A. Scully 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Russell L. Carson 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert A. Ortenzio 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert A. Ortenzio 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert A. Ortenzio 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert A. Ortenzio 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian R. Rusignuolo 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Weigl 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Chernow 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Chernow 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Chernow 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert A. Ortenzio 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert G. Breighner JR 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Weigl 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Weigl 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martin Jackson 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Mullin 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert A. Ortenzio 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Malatesta 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James S. Ely III 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel J. Thomas 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marilyn B. Tavenner 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Saich 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martin Jackson 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martin Jackson 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martin Jackson 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Tyler Hollenbach 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William H. Frist 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-04-24. Item 5.07 · say-on-pay result. As reported: 97.07% (votes for as printed: 110,664,208). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-04-29. Item 5.07 · say-on-pay result. As reported: 90.07% (votes for as printed: 108,011,565). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-04-26. Item 5.07 · say-on-pay result. As reported: 88.29% (votes for as printed: 106,777,980). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 990,908 + equity 1,599,992 + all other 0 = 2,590,900, summed across the director compensation table rows.
- Select Medical Holdings Corp (subject), Section 10b CEO total. DEF 14A, filed 2026-03-04. CEO total compensation as printed in Select Medical Holdings Corp's own proxy. As printed: 3,042,527. View filing ↗